Sabine Tejpar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8751701/publications.pdf

Version: 2024-02-01

236925 214800 10,527 49 25 47 citations h-index g-index papers 53 53 53 14990 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. Nature Medicine, 2015, 21, 1350-1356.	30.7	3,596
2	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncology, The, 2010, 11, 753-762.	10.7	1,915
3	Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nature Reviews Cancer, 2017, 17, 79-92.	28.4	686
4	Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i> Wild-Type Metastatic Colorectal Cancer. JAMA Oncology, 2017, 3, 194.	7.1	555
5	A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Research, 2020, 30, 745-762.	12.0	391
6	Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer. Nature Genetics, 2020, 52, 594-603.	21.4	380
7	Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. Journal of Pathology, 2013, 231, 63-76.	4.5	331
8	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. Gastroenterology, 2015, 148, 88-99.	1.3	273
9	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Research, 2021, 31, 272-290.	12.0	229
10	Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer. Journal of the National Cancer Institute, 2012, 104, 1635-1646.	6.3	227
11	Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. The Lancet Gastroenterology and Hepatology, 2016, 1, 207-216.	8.1	227
12	Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. European Journal of Cancer, 2017, 84, 69-80.	2.8	212
13	ldentification of a Poor-Prognosis <i>BRAF</i> -Mutant–Like Population of Patients With Colon Cancer. Journal of Clinical Oncology, 2012, 30, 1288-1295.	1.6	191
14	Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 2019, 37, 1876-1885.	1.6	169
15	<i>BRAF</i> â€^ <i>V600E</i> Mutant Colorectal Cancer Subtypes Based on Gene Expression. Clinical Cancer Research, 2017, 23, 104-115.	7.0	167
16	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncolmmunology, 2020, 9, 1703449.	4.6	156
17	Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer. Nature Genetics, 2022, 54, 963-975.	21.4	106
18	The ZIC gene family encodes multi-functional proteins essential for patterning and morphogenesis. Cellular and Molecular Life Sciences, 2013, 70, 3791-3811.	5.4	86

#	Article	IF	CITATIONS
19	Transcription Factor Zic2 Inhibits Wnt/ \hat{l}^2 -Catenin Protein Signaling. Journal of Biological Chemistry, 2011, 286, 37732-37740.	3.4	73
20	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. Clinical Cancer Research, 2014, 20, 4499-4510.	7.0	55
21	Virtual chromoendoscopy (I-SCAN) detects more polyps in patients with Lynch syndrome: a randomized controlled crossover trial. Endoscopy, 2017, 49, 342-350.	1.8	36
22	Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. Nature Cancer, 2022, 3, 1052-1070.	13.2	36
23	Oncogenic BRAF, unrestrained by TGF^2 -receptor signalling, drives right-sided colonic tumorigenesis. Nature Communications, 2021, 12, 3464.	12.8	33
24	Zeb2 drives invasive and microbiota-dependent colon carcinoma. Nature Cancer, 2020, 1, 620-634.	13.2	29
25	<i>Zic2</i> mutation causes holoprosencephaly via disruption of NODAL signalling. Human Molecular Genetics, 2016, 25, 3946-3959.	2.9	28
26	BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death and Differentiation, 2021, 28, 3282-3296.	11.2	28
27	\hat{l}^2 -Catenin Overexpression in Dupuytren's Disease Is Unrelated to Disease Recurrence. Clinical Orthopaedics and Related Research, 2009, 467, 838-845.	1.5	26
28	The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling. Oncotarget, 2014, 5, 10070-10083.	1.8	26
29	<i>ZIC1</i> gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. FEBS Letters, 2007, 581, 5122-5126.	2.8	24
30	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer., 2021, 9, e003609.		24
31	Impact of endoscopy system, high definition, and virtual chromoendoscopy in daily routine colonoscopy: a randomized trial. Endoscopy, 2019, 51, 237-243.	1.8	23
32	High-Dosage Tamoxifen as Neoadjuvant Treatment in Minimally Invasive Surgery for Dupuytren Disease in Patients with a Strong Predisposition Toward Fibrosis. Journal of Bone and Joint Surgery - Series A, 2014, 96, 655-662.	3.0	22
33	The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer. Clinical Cancer Research, 2020, 26, 4313-4325.	7.0	22
34	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). European Journal of Surgical Oncology, 2020, 46, 955-966.	1.0	22
35	Improved postoperative outcome of segmental fasciectomy in Dupuytren disease by insertion of an absorbable cellulose implant. Journal of Plastic Surgery and Hand Surgery, 2011, 45, 157-164.	0.8	21
36	Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. Oncotarget, 2017, 8, 4277-4288.	1.8	20

#	Article	IF	CITATIONS
37	Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy. Genes and Immunity, 2021, 22, 108-119.	4.1	17
38	Linked Colour imaging for the detection of polyps in patients with Lynch syndrome: a multicentre, parallel randomised controlled trial. Gut, 2022, 71, 553-560.	12.1	12
39	Establishing a Unified COVID-19 "lmmunome― Integrating Coronavirus Pathogenesis and Host Immunopathology. Frontiers in Immunology, 2020, 11, 1642.	4.8	11
40	Deregulation of ZIC Family Members in Oncogenesis. Advances in Experimental Medicine and Biology, 2018, 1046, 329-338.	1.6	8
41	Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer. Clinical and Translational Medicine, 2021, 11, e401.	4.0	6
42	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	3.2	6
43	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics, 2017, 54, 567-571.	3.2	4
44	Prostatic biopsy-related rectal bleeding refractory to medical and endoscopic therapy definitively managed by catheter-directed embolotherapy: a case report. Journal of Medical Case Reports, 2015, 9, 242.	0.8	3
45	Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURINIS Not Prognostic to Colon Cancer. BioMed Research International, 2015, 2015, 1-8.	1.9	3
46	Real-time diagnostic accuracy of blue light imaging, linked color imaging and white-light endoscopy for colorectal polyp characterization. Endoscopy International Open, 2022, 10, E9-E18.	1.8	2
47	Charting the Course for a New Cancer Clinical Research Culture. Public Health Genomics, 2015, 18, 381-385.	1.0	1
48	A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy. Clinical Journal of Gastroenterology, 2021, 14, 1121-1125.	0.8	1
49	Abstract 1219: Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer, 2013,,.		O